GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amneal Pharmaceuticals Inc (NAS:AMRX) » Definitions » Market Cap

AMRX (Amneal Pharmaceuticals) Market Cap : $2,454 Mil (As of Dec. 13, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Amneal Pharmaceuticals Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Amneal Pharmaceuticals's share price for the quarter that ended in Sep. 2024 was $8.32. Amneal Pharmaceuticals's Shares Outstanding (EOP) for the quarter that ended in Sep. 2024 was 310 Mil. Therefore, Amneal Pharmaceuticals's market cap for the quarter that ended in Sep. 2024 was $2,577 Mil.

Amneal Pharmaceuticals's quarterly market cap increased from Mar. 2024 ($1,870 Mil) to Jun. 2024 ($1,965 Mil) and increased from Jun. 2024 ($1,965 Mil) to Sep. 2024 ($2,577 Mil).

Amneal Pharmaceuticals's annual market cap declined from Dec. 2021 ($716 Mil) to Dec. 2022 ($301 Mil) but then increased from Dec. 2022 ($301 Mil) to Dec. 2023 ($1,861 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Amneal Pharmaceuticals's Enterprise Value for Today is $5,080 Mil.


Amneal Pharmaceuticals Market Cap Historical Data

The historical data trend for Amneal Pharmaceuticals's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amneal Pharmaceuticals Market Cap Chart

Amneal Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Market Cap
Get a 7-Day Free Trial 708.88 674.87 715.69 301.47 1,860.85

Amneal Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 651.34 1,860.85 1,870.26 1,965.32 2,577.29

Competitive Comparison of Amneal Pharmaceuticals's Market Cap

For the Drug Manufacturers - Specialty & Generic subindustry, Amneal Pharmaceuticals's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amneal Pharmaceuticals's Market Cap Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amneal Pharmaceuticals's Market Cap distribution charts can be found below:

* The bar in red indicates where Amneal Pharmaceuticals's Market Cap falls into.



Amneal Pharmaceuticals Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Amneal Pharmaceuticals's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as

Market Cap (A: Dec. 2023 )=Share Price (A: Dec. 2023 )*Shares Outstanding (EOP) (A: Dec. 2023 )
=$6.07*306.565
=$1,861

Amneal Pharmaceuticals's Market Cap for the quarter that ended in Sep. 2024 is calculated as

Market Cap (Q: Sep. 2024 )=Share Price (Q: Sep. 2024 )*Shares Outstanding (EOP) (Q: Sep. 2024 )
=$8.32*309.77
=$2,577

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Amneal Pharmaceuticals  (NAS:AMRX) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


Amneal Pharmaceuticals Market Cap Related Terms

Thank you for viewing the detailed overview of Amneal Pharmaceuticals's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.


Amneal Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
400 Crossing Boulevard, 3rd Floor, Bridgewater, NJ, USA, 08807
Amneal Pharmaceuticals Inc is a global pharmaceutical company operating primarily in the U.S., India, and Ireland. With three reportable segments; Generics, Specialty, and AvKARE - It develop, manufacture, and distribute a diverse portfolio of essential medicines. The Generics segment focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.
Executives
Deborah M. Autor director C/O PARDES BIOSCIENCES, INC., 2173 SALK AVE., SUITE 250, PMB#052, CARLSBAD CA 92008
John Kiely director C/O ZOVIO INC, 1811 E NORTHROP BLVD, CHANDLER AZ 85286
Jason B. Daly officer: SVP, Chief Legal Officer 400 CROSSING BLVD, 3RD FLOOR, BRIDGEWATER NJ 08807
Andrew S Boyer officer: Exec VP, Comm Optns C/O WATSON PHARMA INC, 360 MOUNT KEMBLE AVE, MORRISTOWN NJ 07960
Nikita Shah officer: SVP, Chief HR Officer C/O AMNEAL PHARMACEUTICALS LLC, 400 CROSSING BLVD, BRIDGEWATER NJ 08807
Tpg Gp A, Llc 10 percent owner 301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102
Gustavo Pesquin officer: See Remarks 4 PARK LANE, MADISON NJ 07940
Jon Winkelried 10 percent owner C/O GOLDMAN, SACHS & CO., 85 BROAD STREET, NEW YORK NY 10004
Gautam Patel director C/O AMNEAL PHARMACEUTICALS LLC, 400 CROSSING BLVD, BRIDGEWATER NJ 08807
Chirag K. Patel director C/O AMNEAL PHARMACEUTICALS LLC, 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807
Chintu Patel director C/O AMNEAL PHARMACEUTICALS LLC, 400 CROSSING BOULEVARD, BRIDGEWATER CA 08807
Joseph Todisco officer: SVP, Specialty Commercial 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807
Jeffrey P. George director C/O AMNEAL PHARMACEUTICALS, INC., 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807
Shlomo Yanai director ONE MEADOWLANDS PLAZA, EAST RUTHERFORD NJ 07073
Paul M Meister director 18 SHIP ROCK ROAD, NORTH HAMPTON NH 03862